Ayala Pharmaceuticals Inc. (ADXS)

OTCMKTS: ADXS · Delayed Price · USD
0.700
-0.010 (-1.41%)
Mar 27, 2024, 1:26 PM EDT - Market closed

Company Description

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.

The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Ayala Pharmaceuticals Inc.
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. Ruth Ben Yakar Ph.D.

Contact Details

Address:
9 Deer Park Drive, Suite K-1
Monmouth Junction, New Jersey 08852
United States
Phone 732 545 1590
Website advaxis.com

Stock Details

Ticker Symbol ADXS
Exchange OTCMKTS
Fiscal Year November - October
Reporting Currency USD
CIK Code 0001100397
CUSIP Number 007624307
ISIN Number US0076244062
Employer ID 84-1521955
SIC Code 2834

Key Executives

Name Position
Dr. Ruth Ben Yakar Ph.D. Chief Executive Officer
Dr. Stela Gangrenovitch Ph.D. Co-Founder, Chief Scientist Officer and Director
Mark Gengrinovitch LLB Co-Founder, Chief Financial Officer and Director

Latest SEC Filings

Date Type Title
Mar 5, 2024 8-K Current Report
Mar 5, 2024 DEFM14C Filing
Feb 23, 2024 8-K Current Report
Feb 20, 2024 PREM14C Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 8-K Current Report
Feb 6, 2024 8-K Current Report
Jan 3, 2024 8-K/A [Amend] Current report